Tag Archives: IFPAC

Process Analytical Technology (PAT) in CRO/CMO – Why is it important?

On January 25, 2012, I attended an excellent session at the IFPAC Conference where a series of presenters including Lonza, Hovione, Merck, Pfizer, and Bristol-Myers Squibb presented the value of Process Analytical Technology (PAT) and Quality by Design (QbD) within a CRO/CMO (Contract Research Organization/Contract Manufacturing Organization). Continue reading

IFPAC 2011上谈PAT与颗粒大小分析

2010工艺过程中的颗粒论坛会上的三位报告者将在2011年1月21日于(美国)马里兰州的巴尔的摩举行的IFPAC (工艺过程分析技术国际论坛)上作报告。Johnson & Johnson的Steve Mehrman和Merck & Co. 的James Butz被排在周五上午的“颗粒特征分析超声光谱”IFPAC 的第五分会作报告。Bristol-Myers Squibb的Kevin Macias将在周五上午的“药品开发与生产的控制战略”第七分会中作报告。 Continue reading

PAT & Particle Size Analysis at IFPAC 2011

Three speakers from the 2010 In-Process Particle Forum will present at IFPAC [International Forum Process Analytical Technology] on January 21, 2011 in Baltimore, MD.  Steve Mehrman  of Johnson & Johnson and James Butz of Merck & Co. are scheduled to present during the Particle Characterization/Analysis-Ultrasound Spectroscopy Friday AM V session at IFPAC.  Kevin Macias of Bristol-Myers Squibb will present during the Control Strategies for Drug Product Development and Manufacturing Friday AM VII session. Continue reading